Which has stronger valuation & earnings, AUPH or EIKN?

Aurinia Pharmaceuticals has higher revenue and earnings than Eikon Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aurinia Pharmaceuticals $283.05M 7.19 $287.20M $2.17 7.29 Eikon Therapeutics N/A N/A N/A N/A N/A

Does the media prefer AUPH or EIKN?

In the previous week, Aurinia Pharmaceuticals and Aurinia Pharmaceuticals both had 3 articles in the media. Aurinia Pharmaceuticals' average media sentiment score of 1.16 beat Eikon Therapeutics' score of 0.47 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eikon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, EIKN or TRVI?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eikon Therapeutics N/A N/A N/A N/A N/A Trevi Therapeutics N/A N/A -$42.76M -$0.32 N/A

Is EIKN or TRVI more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Trevi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A Trevi Therapeutics N/A -24.53% -23.37%

Which has higher earnings & valuation, BHC or EIKN?

Bausch Health Cos has higher revenue and earnings than Eikon Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bausch Health Cos $10.27B 0.18 $157M -$3.24 N/A Eikon Therapeutics N/A N/A N/A N/A N/A

Does the media prefer BHC or EIKN?

In the previous week, Eikon Therapeutics had 1 more articles in the media than Bausch Health Cos. MarketBeat recorded 3 mentions for Eikon Therapeutics and 2 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.49 beat Eikon Therapeutics' score of 0.47 indicating that Bausch Health Cos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eikon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, EIKN or MLYS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eikon Therapeutics N/A N/A N/A N/A N/A Mineralys Therapeutics N/A N/A -$154.65M -$2.05 N/A

Is EIKN or MLYS more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Mineralys Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A Mineralys Therapeutics N/A -27.92% -26.98%

Does the media favor EIKN or MLYS?

In the previous week, Mineralys Therapeutics had 8 more articles in the media than Eikon Therapeutics. MarketBeat recorded 11 mentions for Mineralys Therapeutics and 3 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.47 beat Mineralys Therapeutics' score of 0.37 indicating that Eikon Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mineralys Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, EIKN or NTLA?

Eikon Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eikon Therapeutics N/A N/A N/A N/A N/A Intellia Therapeutics $67.67M 25.00 -$412.69M -$3.54 N/A

Does the media prefer EIKN or NTLA?

In the previous week, Eikon Therapeutics and Eikon Therapeutics both had 3 articles in the media. Eikon Therapeutics' average media sentiment score of 0.47 beat Intellia Therapeutics' score of 0.22 indicating that Eikon Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Eikon Therapeutics (EIKN) Competitors

$8.75 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$9.08 +0.33 (+3.77%)

As of 06/12/2026 07:58 PM Eastern

Compare

EIKN vs. AUPH, TRVI, BHC, MLYS, and NTLA

Should you buy Eikon Therapeutics stock or one of its competitors? MarketBeat compares Eikon Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eikon Therapeutics include Aurinia Pharmaceuticals (AUPH), Trevi Therapeutics (TRVI), Bausch Health Cos (BHC), Mineralys Therapeutics (MLYS), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry.

How does Eikon Therapeutics compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Eikon Therapeutics (NASDAQ:EIKN) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Aurinia Pharmaceuticals and Aurinia Pharmaceuticals both had 3 articles in the media. Aurinia Pharmaceuticals' average media sentiment score of 1.16 beat Eikon Therapeutics' score of 0.47 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eikon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aurinia Pharmaceuticals currently has a consensus price target of $17.25, suggesting a potential upside of 9.04%. Eikon Therapeutics has a consensus price target of $25.20, suggesting a potential upside of 188.00%. Given Eikon Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Eikon Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Aurinia Pharmaceuticals has higher revenue and earnings than Eikon Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.19	$287.20M	$2.17	7.29
Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Eikon Therapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Eikon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
Eikon Therapeutics	N/A	N/A	N/A

Summary

Aurinia Pharmaceuticals beats Eikon Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Eikon Therapeutics compare to Trevi Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and Trevi Therapeutics (NASDAQ:TRVI) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Eikon Therapeutics presently has a consensus price target of $25.20, indicating a potential upside of 188.00%. Trevi Therapeutics has a consensus price target of $22.90, indicating a potential upside of 61.15%. Given Eikon Therapeutics' higher probable upside, research analysts plainly believe Eikon Therapeutics is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

95.8% of Trevi Therapeutics shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Eikon Therapeutics' return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
Trevi Therapeutics	N/A	-24.53%	-23.37%

In the previous week, Eikon Therapeutics had 2 more articles in the media than Trevi Therapeutics. MarketBeat recorded 3 mentions for Eikon Therapeutics and 1 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.89 beat Eikon Therapeutics' score of 0.47 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Eikon Therapeutics	Neutral
Trevi Therapeutics	Very Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

Summary

Trevi Therapeutics beats Eikon Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Eikon Therapeutics compare to Bausch Health Cos?

Bausch Health Cos (NYSE:BHC) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

78.7% of Bausch Health Cos shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Bausch Health Cos has higher revenue and earnings than Eikon Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.18	$157M	-$3.24	N/A
Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A

Eikon Therapeutics has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Eikon Therapeutics' return on equity of 0.00% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-11.47%	-2,922.77%	5.63%
Eikon Therapeutics	N/A	N/A	N/A

Bausch Health Cos presently has a consensus target price of $8.00, indicating a potential upside of 58.26%. Eikon Therapeutics has a consensus target price of $25.20, indicating a potential upside of 188.00%. Given Eikon Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Eikon Therapeutics is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, Eikon Therapeutics had 1 more articles in the media than Bausch Health Cos. MarketBeat recorded 3 mentions for Eikon Therapeutics and 2 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.49 beat Eikon Therapeutics' score of 0.47 indicating that Bausch Health Cos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eikon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Eikon Therapeutics beats Bausch Health Cos on 6 of the 11 factors compared between the two stocks.

How does Eikon Therapeutics compare to Mineralys Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

Eikon Therapeutics' return on equity of 0.00% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
Mineralys Therapeutics	N/A	-27.92%	-26.98%

In the previous week, Mineralys Therapeutics had 8 more articles in the media than Eikon Therapeutics. MarketBeat recorded 11 mentions for Mineralys Therapeutics and 3 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.47 beat Mineralys Therapeutics' score of 0.37 indicating that Eikon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mineralys Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

84.5% of Mineralys Therapeutics shares are owned by institutional investors. 18.9% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Eikon Therapeutics presently has a consensus price target of $25.20, indicating a potential upside of 188.00%. Mineralys Therapeutics has a consensus price target of $49.33, indicating a potential upside of 108.86%. Given Eikon Therapeutics' higher possible upside, analysts clearly believe Eikon Therapeutics is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Mineralys Therapeutics beats Eikon Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Eikon Therapeutics compare to Intellia Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

88.8% of Intellia Therapeutics shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Eikon Therapeutics currently has a consensus price target of $25.20, suggesting a potential upside of 188.00%. Intellia Therapeutics has a consensus price target of $20.25, suggesting a potential upside of 67.22%. Given Eikon Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Eikon Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

In the previous week, Eikon Therapeutics and Eikon Therapeutics both had 3 articles in the media. Eikon Therapeutics' average media sentiment score of 0.47 beat Intellia Therapeutics' score of 0.22 indicating that Eikon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intellia Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eikon Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
Intellia Therapeutics	$67.67M	25.00	-$412.69M	-$3.54	N/A

Eikon Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -597.04%. Eikon Therapeutics' return on equity of 0.00% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

Summary

Eikon Therapeutics beats Intellia Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Eikon Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EIKN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EIKN vs. The Competition

Export

Metric	Eikon Therapeutics	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$473.72M	$407.67M	$4.29B	$12.05B
Dividend Yield	N/A	N/A	10.25%	5.66%
P/E Ratio	N/A	N/A	22.29	24.42
Price / Sales	N/A	320.73	159.46	110.47
Price / Cash	N/A	N/A	40.19	37.92
Price / Book	N/A	2.49	26.92	6.82
Net Income	N/A	-$81.71M	$116.61M	$337.56M
7 Day Performance	-2.56%	-0.93%	0.25%	1.17%
1 Month Performance	-33.96%	-12.31%	0.25%	3.16%
1 Year Performance	N/A	N/A	14.23%	30.58%

Eikon Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EIKN Eikon Therapeutics	N/A	$8.75 flat	$25.20 +188.0%	N/A	$473.72M	N/A	N/A	384
AUPH Aurinia Pharmaceuticals	2.5391 of 5 stars	$15.91 +1.6%	$17.25 +8.4%	+93.4%	$2.05B	$283.05M	7.36	300	Positive News
TRVI Trevi Therapeutics	2.8069 of 5 stars	$13.79 +2.1%	$22.90 +66.1%	+133.3%	$1.97B	N/A	N/A	20	Positive News Gap Down
BHC Bausch Health Cos	2.5852 of 5 stars	$5.25 +2.6%	$8.00 +52.5%	-16.0%	$1.96B	$10.27B	N/A	20,300
MLYS Mineralys Therapeutics	3.7473 of 5 stars	$23.60 +4.9%	$49.33 +109.0%	+64.9%	$1.93B	N/A	N/A	28	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EIKN) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eikon Therapeutics (EIKN) Competitors

EIKN vs. AUPH, TRVI, BHC, MLYS, and NTLA

How does Eikon Therapeutics compare to Aurinia Pharmaceuticals?

Summary

How does Eikon Therapeutics compare to Trevi Therapeutics?

Summary

How does Eikon Therapeutics compare to Bausch Health Cos?

Summary

How does Eikon Therapeutics compare to Mineralys Therapeutics?

Summary

How does Eikon Therapeutics compare to Intellia Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN vs. The Competition

Eikon Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eikon Therapeutics (EIKN) Competitors

EIKN vs. AUPH, TRVI, BHC, MLYS, and NTLA

How does Eikon Therapeutics compare to Aurinia Pharmaceuticals?

Do institutionals and insiders hold more shares of AUPH or EIKN?

Does the media prefer AUPH or EIKN?

Do analysts rate AUPH or EIKN?

Which has stronger valuation & earnings, AUPH or EIKN?

Is AUPH or EIKN more profitable?

Summary

How does Eikon Therapeutics compare to Trevi Therapeutics?

Do analysts rate EIKN or TRVI?

Do insiders & institutionals believe in EIKN or TRVI?

Is EIKN or TRVI more profitable?

Does the media prefer EIKN or TRVI?

Which has stronger earnings & valuation, EIKN or TRVI?

Summary

How does Eikon Therapeutics compare to Bausch Health Cos?

Do institutionals and insiders believe in BHC or EIKN?

Which has higher earnings & valuation, BHC or EIKN?

Is BHC or EIKN more profitable?

Do analysts prefer BHC or EIKN?

Does the media prefer BHC or EIKN?

Summary

How does Eikon Therapeutics compare to Mineralys Therapeutics?

Is EIKN or MLYS more profitable?

Does the media favor EIKN or MLYS?

Which has higher earnings & valuation, EIKN or MLYS?

Do institutionals & insiders hold more shares of EIKN or MLYS?

Do analysts prefer EIKN or MLYS?

Summary

How does Eikon Therapeutics compare to Intellia Therapeutics?

Do institutionals and insiders hold more shares of EIKN or NTLA?

Do analysts prefer EIKN or NTLA?

Does the media prefer EIKN or NTLA?

Which has better valuation & earnings, EIKN or NTLA?

Is EIKN or NTLA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN vs. The Competition

Eikon Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools